Application of cord blood-derived anti-CD19 CAR-NK cells resulted in overall response rates (ORR) of 73% in patients with CD19-positive lymphoid tumors, with most patients in complete remission in a Phase 1/2 clinical trial (44). This evidence concerns the gene CD19 and lymphoid neoplasm.